Participants in a pre-exposure prophylaxis (PrEP) trial comparing TDF/FTC (Truvada) with a look-alike dummy pill aimed to take two pills 2 to 24 hours before sex, one pill 24 hours after the first two pills, and one pill 24 hours after the third pill.
Dr. Monica Hahn co-authored a piece called “Special Considerations: The Care of Women and Gender Variant Patients Living with HIV” in the October 2018 issue of HIV Specialist Magazine.
In honor of Father’s Day, we sat down with Shannon Weber, M.S.W., executive director of HIVE and Guy Vandenberg, M.S.W., RN, with the Positive Reproduction Options for Men (PRO Men) project of HIVE and Ward 86 in San Francisco.
Although men who have sex with other men are still most susceptible to HIV in the U.S., women nonetheless made up 19 percent of new diagnoses in 2016. Black women specifically are disproportionately affected by HIV, accounting for 61 percent of women living with the disease and 19 percent of new diagnoses, while making up only about 7 percent of the population.
The Chancellor Award for Public Service in the staff category was awarded to Shannon Weber, who has worked steadfastly on HIV prevention, care and treatment projects.
The prescription of HIV-prevention pills has lagged, and negative biases towards patients could help explain why.